Rank |
Status |
Study |
1 |
Recruiting
|
Comparative Effects of Nebivolol and Metoprolol on Femal Sexual Function
Conditions: |
Hypertension; Female Sexual Dysfunction |
Interventions: |
Drug: nebivolol and Metoprolol succinate; Drug: Metoprolol succinate and nebivolol |
Outcome Measures: |
Change in FSF and CSFQ, two validated questionnaires for assessment of sexual function.; The effects of nebivolol and Metoprolol on sexual function and to compare the effects of both drugs on vitality, work and life performance, and work and life satisfaction. |
|
2 |
Recruiting
|
Influence of CPB and Mini CPB to the Absorption of the Metoprolol
Condition: |
Drug Absorption |
Intervention: |
Drug: blood concentration of Metoprolol |
Outcome Measures: |
absorbtion of the Metoprolol; atrial fibrillation |
|
3 |
Not yet recruiting
|
A Crossover Study to Evaluate the Effect of JNJ-54452840 on Pharmacodynamics of Metoprolol Tartrate Immediate-Release in Healthy Participants
Condition: |
Healthy |
Interventions: |
Drug: Metoprolol tartrate immediate-release (Metoprolol IR); Drug: JNJ-54452840; Drug: Placebo |
Outcome Measures: |
Exercise Heart Rate; Exercise Blood Pressure |
|
4 |
Recruiting
|
Randomized Trial Comparing Diltiazem and Metoprolol For Atrial Fibrillation Rate Control
Conditions: |
Atrial Fibrillation; Atrial Flutter |
Interventions: |
Drug: Metoprolol; Drug: Diltiazem |
Outcome Measures: |
Conversion to sinus rhythm; Heart rate control; Home discharges from Emergency Department (ED); Total hospital cost; Rehospitalization for Atrial Fibrillation |
|
5 |
Not yet recruiting
|
Assessment of Metoprolol in the Prevention of Vasovagal Syncope in Aging Subjects
Condition: |
Vasovagal Syncope |
Interventions: |
Drug: Metoprolol; Drug: Matching Placebo |
Outcome Measures: |
The primary outcome measure will be the proportion of patients having at least one syncope recurrence.; A secondary outcome will be the time between the first and second syncope recurrences.; A secondary outcome will be the frequency of syncopal spells.; A secondary outcome is the number, duration, and severity of presyncopal spells (as measured with the Calgary Presyncope Scale); A secondary outcomes will be quality of life as measured by the EQ-5D and the ISQL. |
|
6 |
Not yet recruiting
|
Comparison of Efficacy of Ivabradine Versus Metoprolol
Condition: |
Coronary Artery Disease |
Intervention: |
Drug: Ivabradine and Metoprolol |
Outcome Measures: |
Heart rate of patient before CT coronary; safety and side effect of Metoprolol and Ivabradine |
|
7 |
Recruiting
|
Genetically Targeted Therapy for the Prevention of Symptomatic Atrial Fibrillation in Patients With Heart Failure
Conditions: |
Atrial Fibrillation; Atrial Flutter |
Interventions: |
Drug: bucindolol hydrochloride; Drug: Metoprolol succinate |
Outcome Measures: |
Time to first event of symptomatic atrial fibrillation/atrial flutter (AF/AFL) or all cause mortality (ACM) during the 24-week Follow-up Period after conversion to stable sinus rhythm (SR); Time to first event of AF/AFL (i.e., symptomatic or asymptomatic) or ACM during the 24-week Follow-up Period; Proportion of patients during the 24-week Follow-up Period with ventricular tachycardia (VT), ventricular fibrillation (VF), or symptomatic supraventricular tachycardia (SVT); Total number of hospitalization (all-cause) days per patient during the Total Study Period; Time to first event of ACM or heart failure (HF) hospitalization (as assessed by the Investigator) during the Total Study Period; Proportion of patients who have AF on ECG at the end of the study who demonstrate ventricular response rate (VRR) control |
|
8 |
Recruiting
|
A Comparison of the Effects of Intraoperative Administration of Metoprolol or Esmolol on General Anesthetic Requirement
Condition: |
Myocardial Ischemia |
Interventions: |
Drug: Metoprolol; Drug: Esmolol; Drug: Placebo |
Outcome Measures: |
Our objective is to clarify if Metoprolol, in a dose range used for perioperative cardiac protection, decreases anesthetic requirement.; Administration of esmolol, a short-acting beta-receptor antagonist, might reduce the actual anesthetic requirement. |
|
9 |
Recruiting
|
Metoprolol Succinate in Cardiac Remodeling Related to Cirrhosis
Conditions: |
Cirrhosis; Cirrhotic Cardiomyopathy; Cardiac Remodeling |
Interventions: |
Drug: Metoprolol succinate; Drug: placebo |
Outcome Measures: |
Improvement of systolic function; Improvement in left ventricular diastolic function; Renal function; Serum level of BNP, catecholamines, plasmatic renin activity; Mortality; Quality of life; Electrophysiologic modifications |
|
10 |
Unknown †
|
Metoprolol and Formoterol in Chronic Obstructive Pulmonary Disease (COPD)
Condition: |
Chronic Obstructive Pulmonary Disease (COPD) |
Intervention: |
Drug: Metoprolol |
Outcome Measures: |
Difference in airway reactivity after treatment with Metoprolol compared to placebo.; Effect of formoterol on airway reactivity comparing Metoprolol with placebo.; Borg-scores during provocation test; Peak-flow measurements; CCQ-scores; Exacerbation rate and rescue medication use |
|
11 |
Recruiting
|
Sarpogrelate Drug Interaction
Conditions: |
Hypertension; Peripheral Artery Disease |
Interventions: |
Drug: Sarpogrelate pretreatment; Drug: Sarpogrelate; Drug: Metoprolol |
Outcome Measures: |
Plasma concentration of Metoprolol and metabolites; Blood pressure and pulse rate changes |
|
12 |
Recruiting
|
Comparison of 2 Beta Blocker Drugs on Peripheral Arterial Disease in Patients With High Blood Pressure
Conditions: |
Peripheral Artery Disease; Hypertension |
Interventions: |
Drug: nebivolol; Drug: Metoprolol succinate |
Outcome Measures: |
Peak Walking Time; Walking Impairment Questionnaire; Ankle-brachial index; markers of inflammation.; Claudication Onset Time |
|
13 |
Recruiting
|
Effects of Nebivolol on Skeletal Muscle During Exercise in Hypertensive Patients
Condition: |
Hypertension |
Interventions: |
Drug: Metoprolol succinate; Drug: Nebivolol; Drug: Hydrochlorothiazide; Drug: DEFINITY®; Procedure: Non-invasive measurement of Cardiac Output (CO); Procedure: Flow mediated vasodilation; Procedure: Endothelial cell collection; Procedure: Microvascular perfusion assessment using Definity |
Outcome Measures: |
Endothelial cell protein expression; Microvascular blood flow; Flow mediated dilation (FMD) |
|
14 |
Recruiting
|
PREvention of Atrial Fibrillation in patientS Undergoing thorAcic surGEry for Lung Cancer
Conditions: |
Lung Cancer; Atrial Fibrillation |
Interventions: |
Drug: Metoprolol; Drug: Losartan |
Outcome Measures: |
Incidence of postoperative atrial fibrillation; Evaluation of NT-proBNP in the days following the start of treatment and post surgery duration of hospital stay |
|
15 |
Unknown †
|
Combined Antihypertensive Therapy and Sexual Dysfunction
Conditions: |
Hypertension; Sexual Dysfunction |
Interventions: |
Drug: Felodipine add Irbesartan; Drug: Felodipine add Metoprolol |
Outcome Measures: |
Female Sexual Function Index (FSFI); International Index of Erectile Function(IIEF); Change of Systolic Blood Pressure in 2 Weeks; Change of Systolic Blood Pressure in 4 Weeks; Change of Systolic Blood Pressure in 8 Weeks; Change of Systolic Blood Pressure in 12 Weeks; Change of Systolic Blood Pressure in 24 Weeks; Change of Systolic Blood Pressure in 48 Weeks; Change of Diastolic Blood Pressure in 2 Weeks; Change of Diastolic Blood Pressure in 4 Weeks; Change of Diastolic Blood Pressure in 8 Weeks; Change of Diastolic Blood Pressure in 12 Weeks; Change of Diastolic Blood Pressure in 24 Weeks; Change of Diastolic Blood Pressure in 48 Weeks; Serum Estradiol in 24 Weeks; Serum Estradiol in 48 Weeks; Serum Testosterone in 24 Weeks; Serum Testosterone in 48 Weeks; Serum MDA in 24 Weeks; Serum MDA in 48 Weeks; Serum 8-OHdG in 24 Weeks; Serum 8-OHdG in 48 Weeks; Serum HNE in 24 Weeks; Serum HNE in 48 Weeks |
|
16 |
Unknown †
|
Coreg CR, Blood Vessel Stiffness and Blood Vessel Function
Conditions: |
Endothelial Function; Diabetes Mellitus; Hypertension |
Interventions: |
Drug: carvedilol; Drug: Metoprolol extended release |
Outcome Measure: |
Effect of Coreg CR compared to Toprol XL on endothelial function, vascular compliance, and parameters of oxidative stress from time of randomization to study drug termination |
|
17 |
Recruiting
|
A Phase Ⅲ Study of Extended-Release Carvedilol Sulfate for the Treatment of Heart Failure
Condition: |
Heart Failure |
Interventions: |
Drug: Extended-Release Carvedilol Sulfate; Drug: Sustained-release Metoprolol Succinate |
Outcome Measures: |
Change From Baseline in left ventricular ejection fraction(LVEF) by ultrasound cardiogram; Change From Baseline in Left Ventricular End Systolic Volume Index; Change From Baseline in Left Ventricular End Diastolic Volume Index; Incidence of Hospitalizations From Exacerbation of Heart Failure; Incidence of Hospitalizations From All Causes; Incidence of Deaths From All Causes; Change From Baseline in New York Heart Association(NYHA)classification |
|
18 |
Unknown †
|
Beta-Blocker Before Extubation
Condition: |
Myocardial Ischemia |
Intervention: |
Drug: Metoprolol |
Outcome Measures: |
The rate of ischemia as judged by ST segment analysis in the 4h following extubation; Rate-pressure product following extubation; Troponin T elevations, the incidence of cardiogenic edema, and the rate of reintubation; Pro-BNP levels |
|
19 |
Recruiting
|
Nebivolol Versus Sustained Release Metoprolol Succinate in Patients With Chronic Kidney Disease
Condition: |
Chronic Kidney Disease |
Intervention: |
|
Outcome Measures: |
Primary Efficacy; Secondary Efficacy |
|
20 |
Unknown †
|
Nebivolol and the Endothelin (ET)-1 System
Conditions: |
Prehypertension; Hypertension |
Interventions: |
Drug: Nebivolol; Drug: Metoprolol; Drug: Placebo |
Outcome Measure: |
ET-1-mediated vasoconstrictor tone |
|